ArticleLab on a chip2015
Pumpless microfluidic platform for drug testing on human skin equivalents.
Article in Lab on a chip, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 101 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
101 citing papers in PubMed.
- A pump-free microfluidic device for integrated multi-functional testing of tumor spheroids.APL bioengineering · 2026Article
- Engineering skin microphysiological systems for transdermal drug screening based on strategic model selection and quantitative prediction roadmaps.Materials today. Bio · 2026Review
- Organ-on-a-chip toxicology.Innovation (Cambridge (Mass.)) · 2026Review
- Immunopathogenesis and Experimental Models of Alopecia Areata: From Mechanistic Insights to Translational Platforms.Clinical reviews in allergy & immunology · 2026Review
- Engineering the Healing Process: Advanced In Vitro Wound Models and Technologies.Biomedicines · 2026Review
- Advances in Bioprinting to Model Immune-Mediated Skin Diseases.Advanced healthcare materials · 2026Review
- In vitro modelling of extracellular matrix changes during skin aging: from static 2D to 3D dynamic microphysiological systems.Microsystems & nanoengineering · 2026Review
- Skin-on-chip: Quo vadis?APL bioengineering · 2025Review
- Engineered Tissue Models to Decode Host-Microbiota Interactions.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- A human skin-on-a-chip platform for microneedling-driven skin cancer treatment.Materials today. Bio · 2025Article
- Advances in Microengineered Platforms for Skin Research.JID innovations : skin science from molecules to population health · 2025Review
- Article
- Organoids/organs-on-chips towards biomimetic human artificial skin.Burns & trauma · 2025Review
- Musculoskeletal Organs-on-Chips: An Emerging Platform for Studying the Nanotechnology-Biology Interface.Advanced materials (Deerfield Beach, Fla.) · 2025Review
- Longevity cosmeceuticals as the next frontier in cosmetic innovation: a scientific framework for substantiating product claims.Frontiers in aging · 2025Review
- 3D Models Currently Proposed to Investigate Human Skin Aging and Explore Preventive and Reparative Approaches: A Descriptive Review.Biomolecules · 2024Review
- Development of a Static Avascular and Dynamic Vascular Human Skin Equivalent Employing Collagen/Keratin Hydrogels.International journal of molecular sciences · 2024Article
- Recreating Human Skin In Vitro: Should the Microbiota Be Taken into Account?International journal of molecular sciences · 2024Review
- Advances in tissue engineering and biofabrication forBioprinting (Amsterdam, Netherlands) · 2023Article
- Microfluidic Systems for Neural Cell Studies.Bioengineering (Basel, Switzerland) · 2023Review
41 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Advances in bio-mimetic in vitro human skin models increase the efficiency of drug screening studies. In this study, we designed and developed a microfluidic platform that allows for long-term maintenance of full thickness human skin equivalents (HSE) which are comprised of both the epidermal and dermal compartments. The design is based on the physiologically relevant blood residence times in human skin tissue and allows for the establishment of an air-epidermal interface which is crucial for maturation and terminal differentiation of HSEs. The small scale of the design reduces the amount of culture medium and the number of cells required by 36 fold compared to conventional transwell cultures. Our HSE-on-a-chip platform has the capability to recirculate the medium at desired flow rates without the need for pump or external tube connections. We demonstrate that the platform can be used to maintain HSEs for three weeks with proliferating keratinocytes similar to conventional HSE cultures. Immunohistochemistry analyses show that the differentiation and localization of keratinocytes was successfully achieved, establishing all sub-layers of the epidermis after one week. Basal keratinocytes located at the epidermal-dermal interface remain in a proliferative state for three weeks. We use a transdermal transport model to show that the skin barrier function is maintained for three weeks. We also validate the capability of the HSE-on-a-chip platform to be used for drug testing purposes by examining the toxic effects of doxorubucin on skin cells and structure. Overall, the HSE-on-a-chip is a user-friendly and cost-effective in vitro platform for drug testing of candidate molecules for skin disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.